A detailed history of Toth Financial Advisory Corp transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Toth Financial Advisory Corp holds 250 shares of EDIT stock, worth $310. This represents 0.0% of its overall portfolio holdings.

Number of Shares
250
Previous 250 -0.0%
Holding current value
$310
Previous $1,000 100.0%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 16, 2024

BUY
$4.67 - $7.28 $1,167 - $1,820
250 New
250 $1,000
Q2 2022

Jul 25, 2022

SELL
$9.99 - $21.35 $999 - $2,135
-100 Closed
0 $0
Q3 2021

Oct 20, 2021

SELL
$39.27 - $72.94 $3,927 - $7,294
-100 Reduced 50.0%
100 $4,000
Q3 2020

Oct 16, 2020

BUY
$28.06 - $37.16 $2,806 - $3,715
100 Added 100.0%
200 $6,000
Q4 2019

Jan 27, 2020

BUY
$19.49 - $32.63 $389 - $652
20 Added 25.0%
100 $3,000
Q3 2019

Oct 15, 2019

BUY
$22.49 - $26.81 $1,799 - $2,144
80 New
80 $2,000

Others Institutions Holding EDIT

About Editas Medicine, Inc.


  • Ticker EDIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,737,200
  • Market Cap $85.2M
  • Description
  • Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...
More about EDIT
Track This Portfolio

Track Toth Financial Advisory Corp Portfolio

Follow Toth Financial Advisory Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Toth Financial Advisory Corp, based on Form 13F filings with the SEC.

News

Stay updated on Toth Financial Advisory Corp with notifications on news.